Access biomarkers in blood…
without drawing a drop
Access biomarkers without drawing blood
DermiSense seeks to disrupt expensive and resource-intensive blood sampling with an innovative low-cost, zero-power patch that extracts dermal interstitial fluid for local analysis or rapid lab tests.
How it works
How it works
How it works
Using a flexible, bio-inert organic composite microneedle patch our technology extracts dermal interstitial fluid at 300% the speed of competing methods without any pain for the user and can access 93% of the same proteins found in blood plasma and serum.
Using a flexible, bio-inert organic composite microneedle patch our technology extracts dermal interstitial fluid at 300% the speed of competing methods without any pain for the user and can access 93% of the same proteins found in blood plasma and serum.
Using a flexible, bio-inert organic composite microneedle patch our technology extracts dermal interstitial fluid at 300% the speed of competing methods without any pain for the user and can access 93% of the same proteins found in blood plasma and serum.
Why DermiSense
Why DermiSense
Why DermiSense
We are focused on a practical solution to analyze important biomarkers that is gimmick free, low-cost, and widely accessible.
We are focused on a practical solution to analyze important biomarkers that is gimmick free, low-cost, and widely accessible.
We are focused on a practical solution to analyze important biomarkers that is gimmick free, low-cost, and widely accessible.
FAQ
FAQ
FAQ
What is dermal interstitial fluid?
The human interstitium is a network of the fluid-filled spaces in our tissue, and is an underutilized source of diagnostic and prognostic health information. The interstitial space connects liquids in our bodies between cell walls, in our tissue, and in our organs. Interstitial fluid (ISF) is a key carrier of immune cells, signaling molecules, proteins, pharmaceuticals, and metabolites. If a drug, biological, or other analytes of interest is to enter or exit a tissue cell, it will pass through the ISF. The ability to analyze the interstitium by measuring and influencing the analytes and drugs it contains opens bold new possibilities for the optimization of human performance as well as the detection and treatment of disease.
Is DermiSense similar to a continuous glucose monitor (CGM)?
No. While CGMs and DermiSense are both focused on analyzing dermal interstitial fluid (ISF), our focus is broader, aiming to simplify and improve the efficiency of diagnostic testing for a range of biomarkers. Unlike CGMs, DermiSense's technology is not designed for continuous monitoring beyond a few hours, but rather for specific, periodic testing that can be done painlessly and quickly, without the need for traditional blood draws.
Can DermiSense's technology be used for all types of diagnostic tests?
DermiSense's technology is currently focused on diagnostics that can be efficiently conducted through dermal interstitial fluid analysis. While it's particularly effective for testing certain biomarkers such as cortisol, it's not designed to replace all types of blood tests. Our ongoing research and development efforts are focused on expanding the range of diagnostics we can offer.
What is dermal interstitial fluid?
The human interstitium is a network of the fluid-filled spaces in our tissue, and is an underutilized source of diagnostic and prognostic health information. The interstitial space connects liquids in our bodies between cell walls, in our tissue, and in our organs. Interstitial fluid (ISF) is a key carrier of immune cells, signaling molecules, proteins, pharmaceuticals, and metabolites. If a drug, biological, or other analytes of interest is to enter or exit a tissue cell, it will pass through the ISF. The ability to analyze the interstitium by measuring and influencing the analytes and drugs it contains opens bold new possibilities for the optimization of human performance as well as the detection and treatment of disease.
Is this a CGM?
No. While CGMs and DermiSense are both focused on analyzing dermal interstitial fluid (ISF), our focus is broader, aiming to simplify and improve the efficiency of diagnostic testing for a range of biomarkers. Unlike CGMs, DermiSense's technology is not designed for continuous monitoring beyond a few hours, but rather for specific, periodic testing that can be done painlessly and quickly, without the need for traditional blood draws.
What biomarkers can be tested?
DermiSense's technology is currently focused on diagnostics that can be efficiently conducted through dermal interstitial fluid analysis. While it's particularly effective for testing certain biomarkers such as cortisol, it's not designed to replace all types of blood tests. Our ongoing research and development efforts are focused on expanding the range of diagnostics we can offer.